Piper Sandler analyst Jason Bednar reiterated a Buy rating on MDxHealth (MDXH – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $3.73.
According to TipRanks, Bednar is an analyst with an average return of -4.2% and a 41.18% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Cooper Co, and Merit Medical Systems.
Currently, the analyst consensus on MDxHealth is a Strong Buy with an average price target of $7.00, an 87.67% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
MDXH market cap is currently $101.8M and has a P/E ratio of -1.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MDxHealth (MDXH) Company Description:
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. It offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.
Read More on MDXH:
- Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
- Is MDXH a Buy, Before Earnings?
- MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
- MDxHealth director Jan Pensaert resigns
- MDxHealth Sees FY23 revenue $70.2M, consensus $69.15M
